Skip to content

GOLD 2026: COPD

International GOLD Current

Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2026 Report (summarised from the Pocket Guide)

Global Initiative for Chronic Obstructive Lung Disease. 2026 Report and Pocket Guide
Summary checked against the source: 2026-11

Read or download the original

Summarised from the GOLD 2026 Pocket Guide, which condenses the full 2026 report. Page numbers are the pocket guide's printed pages.

At a glance

  1. Diagnosis needs spirometry: post-bronchodilator FEV1/FVC <0.7 in the right clinical context. Pre-bronchodilator spirometry can rule COPD out. [p. 3, 8]
  2. Severity of obstruction (GOLD 1–4) by FEV1, and ABE groups by symptoms (mMRC, CAAT) and exacerbations decide treatment. [p. 17–19]
  3. Initial treatment: group A a bronchodilator; groups B and E: LABA + LAMA; consider triple therapy in E if eosinophils ≥300. [Figure 3.8 · p. 27]
  4. Follow-up is driven by persistent dyspnoea or exacerbations, with eosinophils guiding ICS. [Figure 3.9 · p. 28]
  5. Exacerbations: SABA ± SAMA, prednisolone for up to 5 days, antibiotics for 5 days if indicated; NIV for respiratory acidosis (PaCO₂ ≥45, pH ≤7.35). [p. 41, 47]
  6. LTOT only for severe resting hypoxaemia: PaO₂ ≤55 mm Hg (or <60 with cor pulmonale or polycythaemia). [p. 21]
  7. Pulmonary rehabilitation benefits all grades; stop smoking; vaccinate (influenza, pneumococcal, RSV, COVID-19, Tdap, zoster). [p. 21]

Definition and diagnosis

COPD is a heterogeneous lung condition with chronic respiratory symptoms (dyspnoea, cough, sputum, exacerbations) caused by abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive airflow obstruction. It results from gene–environment interactions over a lifetime (GETomics): smoking, household and outdoor air pollution, abnormal lung development and accelerated lung ageing. Precursor states include pre-COPD and PRISm (preserved ratio impaired spirometry). [p. 3]

Severity of airflow obstruction

Grade Post-bronchodilator FEV1 (with FEV1/FVC <0.7)
GOLD 1, mild ≥80% predicted
GOLD 2, moderate 50–79%
GOLD 3, severe 30–49%
GOLD 4, very severe <30%

Adapted from GOLD 2026 Figure 2.10 [p. 17]

Symptoms and the ABE tool

mMRC grade Breathless…
0 Only with strenuous exercise
1 Hurrying on the level or walking up a slight hill
2 Walks slower than peers, or stops for breath at own pace on the level
3 Stops after about 100 m or a few minutes on the level
4 Too breathless to leave the house, or when dressing

Adapted from GOLD 2026 Figure 2.11 [p. 17]

The CAT has been renamed the Chronic Airways Assessment Test (CAAT): 8 items scored 0–5 (cough, phlegm, chest tightness, breathlessness on stairs, home activities, confidence leaving home, sleep, energy), total 0–40. [Figure 2.12 · p. 18]

mMRC 0–1, CAAT <10 mMRC ≥2, CAAT ≥10
≥1 moderate or severe exacerbation in the previous year Group E Group E
No moderate or severe exacerbation Group A Group B

GOLD 2026 lowers the threshold for group E to one moderate or severe exacerbation (earlier editions used two moderate, or one leading to admission).

Adapted from GOLD 2026 ABE assessment tool (Figure 2.13) [p. 19]

Stable COPD: drug treatment

flowchart TD
    I["Initial treatment, maintenance-naive"] --> E["Group E<br/>LABA + LAMA<br/>consider LABA + LAMA + ICS if eos ≥300"]
    I --> A["Group A<br/>a bronchodilator"]
    I --> B["Group B<br/>LABA + LAMA"]
Adapted from GOLD 2026 Figure 3.8 [p. 27]. A single inhaler is preferred for combinations.

Follow-up: continue current treatment unless dyspnoea or exacerbations need optimising. [Figure 3.9 · p. 28]

flowchart TD
    A["LABA or LAMA"] --> B["LABA + LAMA"]
    B --> C["Consider changing device or molecule<br/>Add or escalate non-drug treatment<br/>Consider adding ensifentrine<br/>Look for (and treat) other causes of dyspnoea"]
flowchart TD
    A["LABA or LAMA"] -->|"eos &lt;300"| B["LABA + LAMA"]
    A -->|"eos ≥300"| C["LABA + LAMA + ICS"]
    B -->|"eos ≥100"| C
    B -->|"eos &lt;100"| R["Roflumilast<br/>if FEV1 &lt;50% and chronic bronchitis"]
    B -->|"eos &lt;100"| Z["Azithromycin<br/>preferably in former smokers"]
    C --> R
    C --> Z
    C -->|"2 moderate or 1 severe exacerbation<br/>AND eos ≥300"| BIO["Biologic:<br/>dupilumab (if chronic bronchitis)<br/>mepolizumab"]

Adapted from GOLD 2026 Figure 3.9 [p. 28]. Eosinophils in cells/µL.

When to add ICS

Factors (despite long-acting bronchodilators)
Strongly favours ICS Hospitalisation for an exacerbation; ≥2 moderate exacerbations a year; eosinophils ≥300/µL; history of or concomitant asthma
Favours ICS 1 moderate exacerbation a year; eosinophils 100–<300/µL
Against ICS Repeated pneumonia; eosinophils <100/µL; history of mycobacterial infection

Adapted from GOLD 2026 Figure 3.10 [p. 29]

  • Already on LABA + ICS: no exacerbations and good previous response: continue if symptoms are low, escalate to triple if high. No relevant exacerbation history: consider switching to LABA + LAMA. Current exacerbations: triple therapy if eosinophils ≥100, consider LABA + LAMA if <100. [Figure 3.12 · p. 31]
  • Check inhaler technique and adherence at every visit. [p. 21]
  • De-escalate ICS for pneumonia or other important side effects; de-escalation with eosinophils ≥300 is more likely to bring exacerbations back. [p. 28]

Non-drug treatment

  • Smoking cessation: counselling plus nicotine replacement or drugs; no evidence for e-cigarettes as a quitting aid. [p. 21]
  • Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap if not given in adolescence, zoster. [p. 21]
  • Pulmonary rehabilitation improves exercise capacity, symptoms and quality of life at every grade. [p. 21]
  • LTOT improves survival only with severe resting hypoxaemia: PaO₂ ≤55 mm Hg, or <60 mm Hg with cor pulmonale or polycythaemia; not for moderate desaturation. [p. 21]
  • Long-term NIV for marked daytime hypercapnia, especially after a recent admission. [p. 21]
  • Lung volume reduction (surgical or bronchoscopic) in selected advanced emphysema. [p. 21]

Exacerbations

An exacerbation is worsening dyspnoea and/or cough and sputum over up to 14 days, often with tachypnoea and tachycardia. Look for mimics: pneumonia, pulmonary embolism, acute heart failure, pneumothorax. [p. 41]

Severity (Rome proposal) Features
Mild (default) Dyspnoea VAS <5, RR <24, HR <95, SaO₂ ≥92% on usual oxygen (fall ≤3%), CRP <10 mg/L
Moderate (≥3 of 5) VAS ≥5, RR ≥24, HR ≥95, SaO₂ <92% (or fall >3%), CRP ≥10; ABG may show PaO₂ 70–80 mm Hg
Severe As moderate, plus PaO₂ ≤60 mm Hg and/or PaCO₂ >45 mm Hg with pH <7.35

Adapted from GOLD 2026 Figure 4.2 [p. 43]

Treatment [p. 41]

  • SABA ± short-acting antimuscarinic as first bronchodilators.
  • Systemic corticosteroid for up to 5 days in moderate or severe exacerbations.
  • Antibiotics for 5 days with purulent sputum or previous lung infections.
  • No methylxanthines (side effects).
  • Start long-acting bronchodilators as soon as possible; at discharge, add ICS to dual bronchodilators after ≥1 moderate or severe exacerbation with raised eosinophils.
  • Recovery can take 4–6 weeks.
Support Indications (at least one)
High-flow nasal oxygen Persistent hypoxaemia; can't tolerate NIV or it's contraindicated; weaning from NIV; preventing reintubation
NIV Respiratory acidosis: PaCO₂ ≥6.0 kPa (45 mm Hg) and pH ≤7.35; severe dyspnoea with fatigue (accessory muscles, paradoxical abdomen, recession); persistent hypoxaemia despite oxygen
Invasive ventilation Life-threatening hypoxaemia despite HFNT or NIV; NIV failure or intolerance; after arrest; reduced consciousness or uncontrolled agitation; massive aspiration or vomiting; can't clear secretions; haemodynamic instability; severe arrhythmias

Adapted from GOLD 2026 Figures 4.7–4.9 [p. 47]

Clinical pearls

  • FEV1/FVC <0.7 after bronchodilator confirms COPD; FEV1 grades severity.
  • Group E = ≥1 moderate or severe exacerbation in the past year (2026).
  • ICS by eosinophils: ≥300 strongly favours, <100 argues against.
  • Roflumilast: FEV1 <50% with chronic bronchitis. Azithromycin: former smokers.
  • Exacerbation: systemic steroid up to 5 days, antibiotics × 5 days, NIV at pH ≤7.35 with PaCO₂ ≥45.
  • Admit for respiratory failure, failure of initial treatment, serious comorbidity or poor home support; ICU for worsening gas exchange, confusion, need for intubation or haemodynamic instability.

Classes and levels of evidence

How GOLD 2026 grades its recommendations. Adapted from GOLD 2026 Figure A [full report]. Hover over any class or level cited on this page to see what it means.

Evidence category Meaning
A RCTs and meta-analyses with a rich body of high-quality evidence and no significant limitation or bias
B RCTs and meta-analyses with important limitations, or a limited body of evidence
C Non-randomised trials or observational studies
D Panel consensus judgement, where evidence is insufficient for a higher category

GOLD is a strategy report rather than a graded guideline. The full report tags key statements with an evidence category from A to D; the pocket guide summarised here mostly doesn't, so citations on this page give the pocket-guide page.